Stephens Inc. AR decreased its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 63.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 2,310 shares of the company’s stock after selling 3,962 shares during the period. Stephens Inc. AR’s holdings in Catalent were worth $256,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of CTLT. Parkside Financial Bank & Trust lifted its stake in shares of Catalent by 127.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 282 shares of the company’s stock valued at $36,000 after buying an additional 158 shares during the period. Covestor Ltd purchased a new position in shares of Catalent during the fourth quarter valued at approximately $39,000. Ellevest Inc. lifted its stake in shares of Catalent by 39.5% during the first quarter. Ellevest Inc. now owns 406 shares of the company’s stock valued at $45,000 after buying an additional 115 shares during the period. Sageworth Trust Co of South Dakota purchased a new position in shares of Catalent during the fourth quarter valued at approximately $63,000. Finally, Compagnie Lombard Odier SCmA purchased a new position in shares of Catalent during the first quarter valued at approximately $83,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft cut their price target on shares of Catalent from $129.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $142.86.
Catalent Stock Performance
NYSE:CTLT opened at $110.56 on Friday. The company has a quick ratio of 2.25, a current ratio of 2.89 and a debt-to-equity ratio of 0.90. The company has a market cap of $19.81 billion, a P/E ratio of 40.06, a P/E/G ratio of 1.66 and a beta of 1.28. Catalent, Inc. has a fifty-two week low of $86.34 and a fifty-two week high of $142.64. The firm’s 50 day moving average is $107.32 and its two-hundred day moving average is $103.02.
Catalent (NYSE:CTLT – Get Rating) last issued its earnings results on Tuesday, May 3rd. The company reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.11. Catalent had a net margin of 10.72% and a return on equity of 15.07%. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter last year, the firm posted $0.78 EPS. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. Analysts expect that Catalent, Inc. will post 3.57 EPS for the current year.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.